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with plasma proteins, including coagulation factor X (FX), which binds speciﬁcally to the major Ad5 capsid pro-
tein hexon. FX mediates hepatocyte transduction by intravenously-injected Ad5 vectors and shields vector par-
ticles fromneutralization by natural antibodies and complement. Inmice,mutant Ad5 vectors that are ablated for
FX-binding become detargeted from hepatocytes, which is desirable for certain applications, but unfortunately
such FX-nonbinding vectors also become sensitive to neutralization by mouse plasma proteins. To improve the
properties of Ad5 vectors for systemic delivery, we developed a strategy to replace the natural FX shield by a
site-speciﬁc chemical polyethylene glycol shield. Coupling of polyethylene glycol to a speciﬁc site in hexon hy-
pervariable region 1 yielded vector particles that were protected from neutralization by natural antibodies and
complement although they were unable to bind FX. These vector particles evaded macrophages in vitro and
showed signiﬁcantly improved pharmacokinetics and hepatocyte transduction in vivo. Thus, site-speciﬁc
shielding of Ad5 vectors with polyethylene glycol rendered vectors FX-independent and greatly improved
their properties for systemic gene therapy.
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Recombinant adenovirus vectors, in particular type 5 (Ad5), are fre-
quently used for gene therapy. However, successful systemic delivery of
Ad5-based gene transfer vectors is limited by complex interactions of
the vector with multiple cellular and non-cellular host blood compo-
nents. These interactions result in rapid sequestration of N90% of the
vector particles by the reticuloendothelial system [1]. The sequestration
is causedby opsonization of vector particles due to binding of antibodies
[2–5] and complement components [6,7], uptake of particles by liver si-
nusoidal endothelial cells (LSEC) [1] and liver residential Kupffer cells
(KC) [8–11], and transduction of hepatocytes [12,13]. Furthermore, in
humans and rats Ad5 particles are trapped by erythrocytes [14–16].
Macrophages represent a major sink for i.v. injected vector particles
and contribute to rapid clearance of the vector from blood [8,17], Ad-in-
duced toxicity [18,19] and limited transduction of target tissues [6,20].
The uptake of Ad5 vector particles by macrophages is mainly mediated
by scavenger receptor-A (SR-A) and scavenger receptor expressed on
endothelial cells-I (SREC-I) [6,17,21–23]. Scavenger receptors can bindl).
. This is an open access article undernegatively charged molecules [22] and Ad5 vector particles have a net
negative surface charge that is mainly located in the hypervariable re-
gions (HVRs) of the hexon protein [8,24–27].
In addition to the vector's intrinsic charge pattern, the interaction of
the particles with host blood coagulation factor X (FX) plays a pivotal
role for the biodistribution of Ad5. Blood coagulation FX binds to distinct
amino acid residues in theHVRs of hexon [28]. In vitro it was shown that
capsid-bound FX can mediate transduction of hepatocytes [12] by
bridging the particles to heparan sulfate proteoglycans (HSPGs) [29].
Importantly, recent ﬁndings in mice demonstrated that mutant Ad5
vectors that are unable to bind FX become opsonized and neutralized
by natural IgM antibodies and the classical complement pathway [5].
This ﬁnding indicates that capsid-bound FX provides a shield from com-
plement and natural antibodies. Both natural antibodies and comple-
ment can contribute to the sequestration of Ad5 vector particles by
KC. Xu et al. reported a modest increase in vector uptake by Kupffer
cells upon depletion of vitamin-K-dependent coagulation factors by
warfarin pretreatment of mice [6]. Alba et al. demonstrated increased
Ad5 genome accumulation in liver and spleen 1 h after injection of
FX-binding ablated Ad5 vectors [30]. In sum, the fate of FX binding-ab-
lated vectors remains largely elusive, to our knowledge there are no
studies available to date that examine the effects of FX on thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mutating the Ad5 capsid tomodify its interactionswith FX can have un-
intended effects on vector activity in vivo, and that amore sophisticated
strategy is needed to improve pharmacokinetic proﬁles. Therefore, we
sought to generate vectors that do not bind FX yet are still shielded
from neutralization by natural antibodies and complement.
Many attempts have beenmade to avoid detrimental vector-host in-
teractions bymodifying the vector capsid either genetically or chemical-
ly. The success of genetic modiﬁcations is often limited by structural
constraints of the vector particles. Moreover, genetic modiﬁcations can
typically be employed at only a few sites of the capsid and thus it is dif-
ﬁcult to addressmultiple complex vector-host interactions solely by ge-
netic means. As an alternative, vectors can be chemically modiﬁed with
synthetic polymers that non-speciﬁcally shield the capsid as a whole.
Such cloaked vectors show improved pharmacokinetics but can exhibit
reduced vector infectivity due to the extensive ‘wrapping’ [8,31–35].
These shortcomings emphasize the need for new modiﬁcation strate-
gies in order to generate re-targeted Ad5 vector particles suitable for
i.v. delivery.
To this end, we generated Ad5 vectors with a genetically introduced
cysteine residue in the hypervariable region 1 (HVR1) of hexon, which
enabled position-speciﬁc covalent attachment of only up to 720
maleimide-activatedpolyethylene glycol shielding polymers [36]. In ad-
dition to this minimal geneti-chemical modiﬁcation, the vectors carried
point mutations in the ﬁber knob domain (ΔCAR) to inhibit binding to
the natural coxsackie and adenovirus receptor (CAR) [37], and in
hexon HVR7 (ΔFX) to inhibit binding of blood coagulation factor X
[28]. Finally, by position-speciﬁc coupling of polyethylene glycol (PEG)
moieties to HVR1 we aimed to provide a shield to evade complement-
and natural antibody-mediated neutralization. We hypothesized that
the position-speciﬁc PEGylation might shield the negative charges of
HVR1 and therefore might limit charge-mediated vector sequestration
via scavenger receptors [8,24].
In summary, the position-speciﬁc PEGylation of HVR1 preserved the
infectivity of the vector particle, prevented complement- and natural
antibody-mediated neutralization, and ablated scavenging of the parti-
cles through scavenger receptor-dependent mechanisms. Furthermore,
depending on the PEG size, PEGylation improved the pharmacokinetic
proﬁle and increased transduction of hepatocytes, thus rendered parti-
cles independent of the natural FX shield.
2. Material and methods
2.1. Cell lines and cell culture
A549 cells (ATCC #CCL-243) were cultivated in MEM (Gibco, Carls-
bad, CA). SKOV-3 cells (ATCC #HTB-77) were cultivated in RPMI
(Gibco, Carlsbad, CA). Raw264.7 cells (ATCC #TIB-71) were cultivated
in RPMI (Gibco, Carlsbad, CA). J774A.1 (ATCC #TIB-67) cells were culti-
vated in DMEM (Gibco, Carlsbad, CA). Hepa1–6 (ATCC #CRL-1830) and
N52.E6 cells [38] were cultivated in α-MEM (Gibco, Carlsbad, CA). All
cell culture media were supplemented with 10% fetal calf serum (for
SKOV-3 cells only 5%) and 1% penicillin/streptomycin/glutamine
(Gibco, Carlsbad, CA). Cells were passaged twice a week.
2.2. Adenovirus vectors
Vectors used in this studywere E1-deletedﬁrst generation vectors of
human adenovirus type 5 (based on GenBank AY339865.1, sequence
from nt 1 to 440 and from nt 3523 to 35935). Vector genomes carried
a human CMV promoter-driven EGFP expression cassette subcloned
from pEGFP-N1 (Clontech). Point mutations were introduced using
Red/ET-based homologous recombination (GeneBridges, Heidelberg,
Germany) in electrocompetent Escherichia coli (ElectroMAX™ DH10B
™, Invitrogen, Karlsruhe, Germany). To inhibit the binding of vector par-
ticles to CAR, a point mutation within the ﬁber knob was introduced(Protein ID: AAQ19310.1; tyrosine at position 477was exchanged for al-
anine; sequence: NNSFLDPEAWNFRNGDL; designation: ΔCAR), as de-
scribed previously [37]. To inhibit the binding of vector particles to FX,
a point mutation within HVR7 of the hexon protein was introduced
(Protein ID: AAQ19298.1; glutamic acid at position 451 was exchanged
for glutamine; sequence: ATEFSDKNQIRVGNNFA; designation: ΔFX), as
described previously [28]. To induce a chemical reactivity for position-
speciﬁc PEGylation, a cysteine residue was introduced into HVR1 of
hexon (Protein ID: AAQ19298.1; aspartic acid at position 151 was ex-
changed for cysteine; sequence: EINLEEEDCDNEDEVDE; designation:
HVR1).
2.3. Adenovirus vector puriﬁcation
Ad5 vectors were propagated in N52.E6 cells which
transcomplement E1 [38]. Cells were infectedwith physical multiplicity
of infection (pMOI) 500 and harvested 48 h p.i. Vector puriﬁcation by
CsCl gradient centrifugation was performed as previously described
[36,39]. For cysteine-carrying vectors, lysis buffers contained 5 mM
and discontinuous gradient buffers contained 1 mM TCEP (Invitrogen,
Karlsruhe, Germany) as reducing reagent to prevent aggregation of par-
ticles due to oxidation of cysteines [36]. To purify PEGylated vector par-
ticles, two consecutive discontinuous CsCl gradients were performed;
only the ﬁrst discontinuous gradient buffer was supplemented with
1 μM TCEP. All buffers were degased and argon-saturated.
Physical titers were determined by either optical density at 260 nm,
after vector lysis with 0.5% sodium dodecyl sulfate and heating at 56 °C
for 10 min [40] or by DNA-based slot-blot procedure [41].
2.4. PEGylation of vector capsids
Different sizes (2 kDa, 5 kDa, 20 kDa) of themaleimide-activated lin-
ear polymer PEG (MeO-PEG-mal; IRIS BiotechMarktredwitz, Germany)
were used in a 20-fold molar excess over cysteines of puriﬁed vector
particles. Immediately before mixing with vectors, PEG moieties were
dissolved in a 50 mM HEPES buffer, pH 7.2. Vector:PEG solutions were
incubated for 1 h at room temperature, rotating. Subsequently, samples
were puriﬁed by discontinuous CsCl gradient centrifugation to remove
uncoupled PEG moieties.
2.5. Visualization of proteins by silver staining after SDS-PAGE
1 × 1010 vector particles were mixed with SDS-loading buffer, heat-
ed for 5 min at 70 °C and loaded on an 8% separation/5% stacking SDS
gel, running at 80 V. Silver staining of separated vector proteins was
done as previously described [42].
2.6. Transduction assays
Transduction assayswere performed usingA549 cells, Hepa1–6 cells
or SKOV-3 cells. 2 × 104 cells/well were seeded on coated, ﬂat bottom
96-well plates (NUNC, Langenselbold, Germany) and cultivated over-
night. The following day cellswerewashedwith PBS, and supplemented
with 100 μl serum-free medium containing no or 8 μg/ml of human FX
(CellSystems Biotechnologie, Troisdorf, Germany). Cells were trans-
duced with pMOI 1000 in triplicates, incubated for 3–4 h at 37 °C,
washed with PBS and 200 μl serous medium was added. Cells were in-
cubated for 24 h (for SKOV-3 cell 72 h), harvested and EGFP expression
was analyzed by ﬂow cytometry (Beckman Coulter Gallios Flow
Cytometer).
2.7. Real-time quantitative PCR analysis
DNA samples were analyzed for their vector DNA content by quanti-
tative real time PCR of the E4 region of the vector genome and normal-
ization using β-actin copy numbers. Therefore 10 μl of Kapa SYBR FAST
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ny), 0.4 μl of 10 pmol/μl primer forward and reverse (for E4: forward
5′-tagacgatccctactgtacg-3′; reverse 5′-ggaaatatgactacgtccgg-3′; for mu-
rine β-actin: forward 5′-caaggagtgcaagaacacag-3′; reverse 5′-
gccttggagtgtgtattgag-3′; for human β-actin: forward 5′-
gctcctcctgagcgcaag-3′; reverse 5′-catctgctggaaggtggaca-3′) and 2 μl
sample were mixed in a ﬁnal volume of 20 μl.
PCR cycles were performed as follows: 1 cycle: 10 min 95 °C (dena-
turation); 40 cycles: 30 s 95 °C (denaturation) − 30 s 60 °C (anneal-
ing)− 20 s 72 °C (elongation).2.8. Surface plasmon resonance analysis
Surface plasmon resonance analysis was performed using a
SR7500DC Dual Channel Surface Plasmon Resonance Spectrometer
(Reichert Technologies Life Sciences, Buffalo, NY, USA) at 25 °C.
Human FX was coated on a carboxymethyldextran hydrogel-coated
CMD500m gold chip with a medium carboxylate density and amax. ca-
pacity of 40.000 response units (RU) (XanTec bioanalytics GmbH,
Düsseldorf, Germany). After repeated injections of running buffer
(10 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 0.005% Tween20, pH 7.4)
at a ﬂowrate of 25 μl/min at 25 °C for 10 min, the left and right surfaces
were activated by ﬂowing a 1:1 mixture of 0.1 M 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimid and 0.1 M Sulfo-NHS in 5 mMMES
buffer pH 6 at a ﬂowrate of 25 μl/min for 4 min. Subsequently, 59 μg/
ml FX diluted in 5 mM NaAc buffer, pH 4.9 were injected onto the left
surface only, at a ﬂowrate of 10 μl/min for 5 min. Uncoated carboxyl
groups were quenched by injection of 1 M ethanolamine, pH 8.5 onto
both surfaces at a ﬂowrate of 25 μl/min for 4 min. The right surface
(which was only activated and quenched in absence of a ligand) served
as the reference surface i.e. the reference signals from the right surface
were subtracted from the signals achieved on the FX-surface (left) to
achieve reference subtracted responses. Glycerol of vector particle solu-
tionswas removed using PDMiniTrapG-25 columns (Amersham, Buck-
inghamshire, UK) according to the manufacturer but without ﬁlter.
Vectors were diluted in running buffer, supplemented with TCEP in a
10-fold molar excess over cysteine and Ca2+ concentrations were ad-
justed to 5 mM. Different vector dilution series were injected (single
values or duplicates; 1 × 109 VP/μl; 1 × 109 VP/μl; 5 × 108 VP/μl;
5 × 108 VP/μl; 2.5 × 108 VP/μl; 1.25 × 108 VP/μl) at a ﬂowrate of 25 μl/
min for 3 min. Each vector injection was followed by injection of regen-
eration buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005%
Tween20, pH 7.4) at a ﬂowrate of 25 μl/min for 50 s.
Saturation of the FX-coated chip by Ad injection was not reached
with the used conditions. Since the quality of the FX surface decreased
over time (compare repeated Ad-wtcapsid injections at same concen-
tration S1a–h), Ad-wtcapsid vectors with a concentration of 1 × 109
VP/μl were injected once before each vector dilution series as a refer-
ence to determine the binding capacity of the FX surface at different
time points. Binding of modiﬁed vectors to FX was quantiﬁed by nor-
malizing the response of the various modiﬁed vectors at concentrations
of 1 × 109 VP/μl to themeasured response of the reference Ad-wtcapsid
vector, which had been injected immediately before.2.9. ZetaSizer measurement
2 × 1011 VP were diluted in 1ml buffer (50mMHEPES, 0.1 mMDTT,
pH 7.4). Glycerol of vector particle solutions was removed using PD
MiniTrap G-25 columns (Amersham, Buckinghamshire, UK) according
to the manual but without ﬁlter. Vector solutions were injected in a
clear disposable zeta cell (DTS1070, Malvern, Worcestershire, UK).
The zeta potential was measured using a ZetaSizer Nano-ZS
(Malvern, Worcestershire, UK) at 25 °C and analyzed with DTSNano
5.10 software.2.10. Vector binding to human blood cells
1 × 108 VP diluted in PBS± 10mg/ml human intravenous IgG (IVIG,
Privigen, CSL Behring, Marburg, Germany) in a ﬁnal volume of 100 μl
were incubated for 30 min at 37 °C rotating with 200 μl human whole
blood of three healthy donors, ELISA-tested to be Ad-naïve. Blood was
anti-coagulatedwith 50 μg/ml Lepirudin (Celgene,Windsor, UK) to pre-
serve complement activity. Subsequently, cells and plasma were sepa-
rated by centrifugation for 10 min at 500 ×g. 20 μl of each fraction
were diluted in PBS in a ﬁnal volume of 200 μl.
To identify the blood cell type to which the vector particles were at-
tached, 20 ml of ELISA-tested anti-Ad IgG-positive hirudinized human
whole blood were incubated with 1 × 1010 Ad-HVR1 vector particles
in a ﬁnal volume of 30 ml for 30 min at 37 °C rotating. Subsequently,
blood samples were carefully layered onto 5 ml bicoll separation solu-
tion (Biochrom, Berlin, Germany) and plasma, leukocytes and erythro-
cytes were separated by centrifugation for 30 min at 500 ×g at 20 °C
without brake. Plasma and blood cells were isolated and cells were
washed twice with 10 ml PBS. 20 μl plasma, 1 × 105 leukocytes or
6.7 × 107 erythrocytes were diluted in PBS in a ﬁnal volume of 200 μl
each.
The DNA of all samples was isolated using GenEluteMammalian Ge-
nomic DNA miniprep Kit (Sigma-Aldrich, Steinheim, Germany), and
stored at−80 °C in 10mM Tris buffer pH 8.0. The Ad5 genome content
of the samples was determined by qPCR analysis and normalized using
human β-actin copy numbers. β-actin was detectable in the plasma
samples prepared as described above and thus exploited for
normalization.
2.11. Animals
Female BALB/c mice at the age of 8–10 weeks were used to analyze
pharmacokinetics and liver transduction. Animals (received from
Charles River, Sulzfeld, Germany) were maintained in pathogen-free,
individually ventilated cages (Tecniplast, Hohenpreissenberg, Germa-
ny) and fedwith sterilized diet for laboratory rodents (Ssniff, Soest, Ger-
many). All experiments were in accordance with policies and
procedures of institutional guidelines and approved by the Animal
Care Commission of the Government Baden-Württemberg or the FDA
Center for Biologics Evaluation and Research Animal Care and Use Com-
mittee. For ﬂuorometic analysis of the liver also antibody-deﬁcient JHD
[43] mice on BALB/c background were bred at FDA. Whole blood sam-
ples of the strains C57BL/6, NMRI, BALB/c or antibody-deﬁcient
muMT−/− (B6. 129S2-Igh-6tm1Cgn/J; JAX Mice Database: 002288)
mice were a kind gift of neighboring working groups of Ulm University.
muMT−/−micewere developed by disruption of an exon of the immu-
noglobulin heavy chain of the IgM antibody class. Mice are lacking ma-
ture B cells and have almost undetectable serum levels of IgG1, IgG2a,
IgG2b, IgG3, IgM and IgA. Blood samples were anticoagulated using
50 μg/ml Lepirudin (Celgene Europe Ltd.,Windsor, UK). Plasma samples
was prepared by pelleting the cells for 10 min at 500 ×g.
2.12. Pharmacokinetics
BALB/c mice were anesthetized by intraperitoneal injection of
150 mg/kg ketamine and 30 mg/kg xylazine. 2 × 1010 VP diluted in
PBS in a ﬁnal volume of 200 μl, were injected into the dorsal tail vein
of mice. After 2, 4, 6, 10 and 20 min small blood samples of 20 μl were
collected in heparinized glass capillaries from the lateral tail veins by
snipping the tail. Samples were mixed with PBS in a ﬁnal volume of
200 μl. Genomic DNA of samples was extracted using GenElute Mam-
malian Genomic DNA Miniprep Kit (Sigma-Aldrich, Steinheim, Germa-
ny), and stored at −80 °C in 10 mM Tris buffer pH 8.0. To analyze
blood cell association, 100 μl whole blood was collected by puncturing
the heart at 20 min p.i. Samples were centrifuged at 800 ×g for
10 min, supernatants discarded, and cells were resuspended in a ﬁnal
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tent of all samples was determined by qPCR analysis and normalized
using murine β-actin copy numbers. Calculations of area under the
curve (AUC) between 2 min and 20 min were done using SciDAVis
1.D5 software (integration by linear interpolation for curve ﬁtting).
2.13. Fluorometic analysis of liver homogenates
2 × 1010 VP diluted in PBS in a total volume of 200 μl were injected
into the dorsal tail vein of BALB/c mice. Mice were sacriﬁced 72 h p.i.
by isoﬂurane (Forene, Abbott, Ludwigshafen, Germany) inhalations
and subsequent liver perfusion with PBS. Fluorometric analysis of the
EGFP expression intensity in the liver tissue was done as previously de-
scribed [44].
For ﬂuorometic analysis of liver homogenates of JHD mice, the ani-
mals were anesthetized by i.p. injection of 150 mg/kg ketamine and
30 mg/kg xylazine 10 min prior to sacriﬁce. Livers were harvested and
200 mg tissue were homogenized in 0.4 ml ice-cold lysis buffer
(25 mM Tris-phosphate pH 7.6, 2 mM EDTA, 10% Glycerol, 1% Triton
X-100, 1/100 protease inhibitor cocktail (Thermo Scientiﬁc
#1861279)) and 0.8 g of 0.5 mm zirconium oxide beads at speed 10
for 2 min using a bullet blender (Next Advance, Inc.). 100 μl of 1:20
and 1:200 diluted lysate were transferred to a black 96-well ﬂat bottom
plate (Greiner Bio One). EGFP ﬂuorescence was measured at 490/510–
570 nm with the Blue Optical Kit of Turner Biosystems. Values were
expressed as arbitrary units of luminescence per mg protein (AU/mg
protein). Protein concentrations of liver lysate were determined by
BIO-RAD DC Protein Assay Kit (BIO-RAD Laboratories, Hercules, CA
94547, USA).
2.14. Fluorescence microscopy of liver and spleen sections
Fluorescence microscopy of murine liver and spleen sections were
done as previously described [39].
2.15. Uptake by macrophages
1 × 105 cells/well of the murine macrophage cell lines Raw264.1 or
J774A.1 were seeded on coated, ﬂat bottom 24-well plates (NUNC,
Langenselbold, Germany) and cultivated overnight. The following day,
cells were washed with PBS, and supplemented with 500 μl serum-
free medium. 2 × 108 vector particles (corresponding to pMOI 2000 in
this assay) were pre-incubated in a ﬁnal volume of 30 μl with PBS or
hirudinized (50 μg/ml, dissolved in PBS) plasma with preserved com-
plement activity of either C57BL/6 or antibody-deﬁcient muMT−/−
mice for 20 min at 37 °C. The complement system of plasma samples
was destroyed by heating (56 °C for 30min). Raw264.7 cells were incu-
bated with the vector:PBS or vector:plasma solution for 2 h at 37 °C.
J774A.1 cells were treated or not with 30 μg/ml poly-(I) (Sigma-Aldrich,
Steinheim, Germany) for 1 h at 37 °C. Subsequently, J774 cells were in-
cubated with 2 × 108 vector particles (pMOI 2000) for 2 h. J774 cells
were washed and incubated for 24 h at 37 °C. Genomic DNA of samples
was extracted using GenElute Mammalian Genomic DNA Miniprep Kit
(Sigma-Aldrich, Steinheim, Germany). Samples were stored at−80 °C
in 10 mM Tris buffer pH 8.0. The vector DNA content of the samples
was determined by qPCR analysis and normalized using murine β-
actin copy numbers.
2.16. Neutralization of vector particles
2 × 104 cells/well A549 were seeded on coated, ﬂat bottom 96-well
plates (NUNC, Langenselbold, Germany) and cultivated overnight. The
following day, cells were washed with PBS, and supplemented with
100 μl serum-free medium. 2 × 107 vector particles dissolved in 1–2 μl
PBS were mixed with 15 μl PBS or hirudinized plasma with preserved
complement activity of either C57BL/6, antibody-deﬁcientmuMT−/−mice or human plasma from healthy donors tested by ELISA to be posi-
tive for anti-Ad5 IgGs (n = 3) or Ad-naïve (n = 3). The complement
system of plasma samples was destroyed by heating (56 °C for
30 min). For titration assays 2 × 107 vector particles dissolved in 1–
2 μl PBS were mixed with 1, 2, 5, 10 or 15 μl of C75BL/6 plasma. Cells
were transduced with pMOI 1000 and incubated for 24 h. EGFP expres-
sion was analyzed by ﬂow cytometry.2.17. ELISA for C3 detection
96 well ﬂat bottom plates (NUNC-Maxisorp, Langenselbold, Germa-
ny) were coated overnight at 4 °C with 3 × 109 VP in 0.2 M carbonate-
bicarbonate, pH 9.6 and then blocked with SuperBlock (PBS) Blocking
Buffer (Thermo Scientiﬁc #37515, Rockford, USA) for 2 h at room tem-
perature. To test the coating efﬁciency, Ad5 ﬁber was detected with
monoclonal mouse anti-Ad5 ﬁber antibody (1:300; AM00311PU-N,
Acris, Herford, Germany) and HRP-conjugated polyclonal rabbit anti-
mouse antibody (1:1.000; Sigma-Aldrich, A9044, Steinheim, Germany).
For C3 ELISAs, plates were incubated with hirudinized murine plasma
(diluted 1:5 in PBS with 2% BSA, 0.05% Tween20, 0.5 mM Mg2+ and
0.9 mM Ca2+) for 1 h at room temperature. Murine C3b was detected
with monoclonal rat anti-mouse C3b antibody (1:1.000; Cedarlane Lab-
oratories Ltd., Burlington,Ontario, Canada; cloneRmC11H9; detects also
C3, iC3b, and C3dg) and HRP-conjugated goat anti-rat antibody
(1:1.500; Sigma-Aldrich, A9037, Steinheim, Germany). Plates were de-
velopedwith o-Phenyldiaminedihydrochloride (Sigma, Steinheim, Ger-
many)/H2O2 substrate and stopped with 1 M sulfuric acid. Absorbance
was measured at 491 nm/620 nm.2.18. Toxicity assay for IL-6
300 μl hirudinized murine whole blood of C57BL/6 mice was incu-
bated with 4 × 109 VP dissolved in 2 μl PBS for 6 h at 37 °C, rotating.
Samples were centrifuged for 10 min at 1.000 ×g. The IL-6 concentra-
tion in the plasma fraction was determined by OptEIA Mouse IL-6
ELISA Kit (BD Biosciences, 550950, San Jose, CA, USA) according to
manufacturer's instructions.2.19. Ad particle size measurements
Vector particle size was determined with a NanoSight LM10 instru-
ment equipped with a red laser and Allied Vision Technologies camera
(NanoSight, Amesbury, UK). Settings were used according to
Kramberger et al. 2012 (except: brightness = 0) [45]. PCS Control
L100 (Beckman Coulter, Fullerton, CA) Latex beads with a diameter of
100 nm and a concentration of 1.4 × 106 beads/μl were used as quality
control. Vectors were diluted in 50 mM HEPES, 10 mM TCEP buffer
pH 7.2 to a ﬁnal concentration of 1.5 × 106 to 1.9 × 106 particles/μl.
Buffers were ﬁltered (0.2 μm), degased and argon-saturated before
use. 300 μl of the vector samples were injected into the LM10 unit
using a sterile syringe. Sample videos were recorded for 60 s and ana-
lyzed with the Nanoparticle Tracking and Analysis (NTA) 2.3 software.
The temperature was measured with an OMEGA HH804 device
(Omega Engineering, Stanford, CA, USA).2.20. Statistics
Results are given as mean ± standard deviation. Statistical analysis
was performed using unpaired two-sample (Welch) student's t-test.
Calculations were done with RStudio-software Version 2.15.0 [46]. P-
values ≤ 0.05 were considered statistically signiﬁcant. Calculations of
AUC-valueswere doneusing SciDAVis 1.D5 software (integration by lin-
ear interpolation for curve ﬁtting).
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3.1. Physical and biological characterization of geneti-chemically modiﬁed
vector particles
We generated EGFP-expressing ΔE1 ﬁrst-generation Ad5 vectors
carrying three different point mutations to analyze interactions of Ad5
with cellular and non-cellular blood components in vitro and in vivo.
The ﬁrst point mutation (ΔCAR; ﬁber Y477A) reduced binding of the
vector particles to their primary receptor CAR. The second mutation
(ΔFX; hexonHVR7 E451Q) inhibited binding of blood coagulation factor
X to hexon, and the third mutation (HVR1; hexon HVR1 D151C) intro-
duced the chemical reactivity for position-speciﬁc PEGylation in form
of a thiol group (Table 1). Vectors were PEGylated withmaleimide-acti-
vated thiol-reactive PEG moieties of different sizes (2000 Da (2K),
5000 Da (5K) and 20,000 Da (20K)) and puriﬁed by CsCl gradient cen-
trifugation to remove uncoupled PEG. Coupling efﬁciency and speciﬁci-
ty were determined by SDS-PAGE and silver staining, and the results
conﬁrmed a near-quantitative PEGylation of the monomeric hexon
(for representative staining see Fig. 1a). Thus, vector particles were
modiﬁed with ~700 PEG moieties/particle at deﬁned positions.
We performed extensive biophysical characterization of the vector
particles to analyze the inﬂuence of PEGylation on surface charges and
particle sizes. Zeta potentialmeasurements revealed that neither the in-
troduced cysteine nor the ΔFX mutation altered the surface charge of
particles compared to an Ad-wtcapsid vector (Fig. 1b). However,
PEGylation signiﬁcantly reduced the negative surface charge of the par-
ticles in a PEG size-dependent manner (unPEG: −37 ± 1.8 mV; 2K-
PEG: −26 ± 1.1 mV, p b 1.1 × 10−5; 5K-PEG: −23 ± 2.5 mV,
p b 1.6 × 10−5; 20K-PEG: −7 ± 0.9 mV, p b 6.1 × 10−8). NanoSight
measurements revealed an increase of the hydrodynamic particle diam-
eter by up to 20%, which was positively correlated with the PEG size
(Table 2). In vitro transduction assays in CAR-expressing A549 cells
showed that neither the ΔFX mutation nor the introduced cysteine ab-
lated the ability of the vectors to transduce cells via CAR (Fig. 1c). In con-
trast and as expected, the ΔCAR mutation reduced transduction by
approximately 100-fold (Fig. 1c). Importantly, PEGylation of HVR1
with PEGmoieties ≤5K did not reduce vector infectivity. However, vec-
tors PEGylatedwith 20K PEG barely transduced cells (for representative
data see Fig. 1d). Results were conﬁrmedwith Hepa1–6 cells, which are
of murine origin (data not shown). The data demonstrated that posi-
tion-speciﬁc capsid modiﬁcation with only ~700 molecules can main-
tain vector infectivity (5K-PEG) even though it signiﬁcantly changed
the charge and size of particles. This is in contrast to earlier approaches
that involved up to 14,000 modiﬁcation sites per particle [32,34,35].
3.2. Ablation of FX-binding by minimal geneti-chemical modiﬁcation
Surface plasmon resonance (SPR) analysis was performed to analyze
binding of unPEGylated and PEGylated Ad-HVR1 and Ad-HVR1-ΔFX
vector particles to FX (Figs. 2a and S1). UnPEGylated Ad-HVR1 vector
particles bound to FX to an extent similar to Ad-wtcapsid particles
(rel. response units (RU) in %: 93.5 ± 7.0%). UnPEGylated Ad-HVR1-
ΔFX vectors, however, showed a signiﬁcantly reduced binding to FX
(rel. RU in %: 17.2 ± 0.6%), which is in agreement with work by AlbaTable 1
Overview of generated mutant Ad5 vectors.
Vector designation Modiﬁcation





Ad-HVR1-ΔCAR-ΔFX ●et al. [28]. PEGylated Ad-HVR1 vector particles exhibited reduced bind-
ing to FX in a PEG size-dependentmanner (rel. RU in %: 2K-PEG: 38.9±
1.9%; 5K-PEG: 7.7 ± 0.8%; 20K-PEG: 3.3 ± 0.8%). Interestingly,
PEGylation of Ad-HVR1-ΔFX vectors, i.e. the combination of the ΔFX
mutation with PEGylation of HVR1, decreased binding to FX to baseline
(rel. RU in %: 2K-PEG: 5.9 ± 0.3%; 5K-PEG: 4.7 ± 0.7%; 20-PEG: 5.5 ±
1.5%).
Transduction assays were performed to assess biological effects of
altered FX-binding in vitro (Fig. 2b, supplementary info for the assay
in Fig. S2). To exclude a CAR-mediated transduction, ΔCAR vectors
were used. The presence of physiological concentrations of FX augment-
ed the transduction by unPEGylated, 2K-, and 5K-PEGylated Ad-HVR1-
ΔCAR vectors, whichwas in agreement to the biophysical data obtained
by SPR analysis. Surprisingly, the vector 2K-PEG-Ad-HVR1-ΔCAR exhib-
ited a very strong transduction in the presence of FX, whichwas corrob-
orated in SKOV-3 cells (Fig. S3). In contrast, unPEGylated and 2K-
PEGylated Ad-HVR1-ΔCAR-ΔFX vectors showed only a modestly en-
hanced transduction of cells in the presence of FX. 5K-PEG-Ad-HVR1-
ΔCAR-ΔFX vectors did not show augmented transduction of cells in
the presence of FX and 20K-PEGylated Ad-HVR1-ΔCAR and 20K-
PEGylated Ad-HVR1-ΔCAR-ΔFX vector particles did not transduce cells
at all. These biological in vitro assays complemented the results of the
SPR analysis: thiol-directed PEGylation of HVR1 reduced FX-binding in
a PEG size-dependent manner. 5K-PEGylation of HVR1 in combination
with aΔFXmutation resulted in undetectable binding to FX and ablated
its biological effects in vitro butmaintained vector infectivity per se. Vec-
tor particles PEGylatedwith 20K-PEG at HVR1 did not bind to FX but lost
infectivity.
3.3. FX-independent hepatocyte transduction by PEGylated vectors in vivo
FX plays an important role for hepatocyte transduction by adenovi-
rus type 5 in vivo [12,13]. Since the modiﬁed vectors showed a reduced
(2K- and 5K-PEGylated Ad-HVR1, unPEGylated and 2K-PEGylated Ad-
HVR1-ΔFX, Fig. 2a) or completely ablated FX-binding (20K-PEGylated
Ad-HVR1, 5K- and 20K-PEGylated Ad-HVR1-ΔFX, Fig. 2a) we analyzed
their capacity to transduce hepatocytes in vivo. 2 × 1010 VP were
injected into the tail vein of BALB/c mice and the EGFP expression
level in liver homogenates was quantiﬁed 72 h p.i. by ﬂuorometic anal-
ysis (Fig. 3a). EGFP expression levels in liver were comparable after in-
jection of unPEGylated Ad-HVR1-ΔCAR and the control vector Ad-
wtcapsid. In contrast, only background ﬂuorescence levels were detect-
ed after injection of unPEGylated Ad-HVR1-ΔCAR-ΔFX. Surprisingly,
highest EGFP expression levels were detected in livers after injection
of 2K-PEGylated Ad-HVR1-ΔCAR or 2K- and 5K-PEGylated Ad-HVR1-
ΔCAR-ΔFX vectors (compared to unPEGylated counterparts: 2K-PEG-
Ad-HVR1-ΔCAR: 35-fold increase, p b 0.006; 2K-PEG-Ad-HVR1-ΔCAR-
ΔFX: 60-fold increase, p b 3.7 × 10−8; 5K-PEG-Ad-HVR1-ΔCAR-ΔFX:
177-fold increase, p b 0.003). Of note, the EGFP expression in liver me-
diated by 5K-PEG-Ad-HVR1-ΔCAR-ΔFX did apparently not depend on
FX (Fig. 3a). 20K-PEGylated vectors did not transduce the liver.
To conﬁrm the results obtained by ﬂuorometic analysis, liver cryo-
sections were prepared and EGFP expression was analyzed in direct
ﬂuorescence images (Fig. 3b). The results corroborated increased trans-






Fig. 1.Near quantitative position-speciﬁc PEGylation of HVR1 reduced the negative surface charge of Ad5 particles butmaintained vector infectivity with PEG ≤ 5 kDa. (a) Silver staining of
1 × 1010 VP PEGylated or unPEGylated Ad-HVR1 vector particles, separated on an 8% SDS-PAGE under denaturing conditions. PEG size-dependent increase of themolecular weight of the
monomeric hexon.M:marker (b) Surface charge of Ad-wtcapsid and unPEGylated or PEGylated vector particles analyzed by ZetaPotential measurements (n= 5). (c) Transduction assay
using Ad-wtcapsid, Ad-HVR1, Ad-HVR1-ΔCAR, and Ad-HVR1-ΔFX. A549 cells were transduced with pMOI 1000, harvested 24 h p.i. and EGFP expression was analyzed by ﬂow cytometry
(n= 3). (d) Transduction assay using PEGylated Ad-HVR1 vectors. A549 cells were transducedwith pMOI 1000, harvested 24 h p.i. and EGFP expression was analyzed by ﬂow cytometry
(n = 3). Results are given as mean ± standard deviation. MFI: mean ﬂuorescence intensity, AU: arbitrary units, unPEG: unPEGylated, *p ≤ 0.05,**p ≤ 0.005, ***p ≤ 0.0005.
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mented transduction of spleen cells by vectors PEGylated with 2K- or
5K-PEG compared to control or unPEGylated vectors (Fig. 3b). 20K-
PEG-Ad-HVR1-ΔCAR-ΔFX vectors did not transduce the spleen.
In brief, the data demonstrated that vector-bound FX is not a strict
requirement for liver transduction by Ad5-based vectors.
3.4. PEGylation can substitute FX to prevent vector neutralization by mu-
rine natural antibodies and complement
Recently, Xu et al. demonstrated that ablation of FX-binding ren-
dered vector particles susceptible to neutralization by mouse plasma
— a process that depends on natural IgM and the classical complement
pathway [5]. Therefore, we analyzed the susceptibility of the PEGylated
vector particles for neutralization by plasma from Ad-naïve C57BL/6 orTable 2
PEG size-dependent increase of hydrodynamic vector particle diameter upon PEGylation
ofHVR1. Particle sizesweredetermined usingNanoSight LM10withNanoparticle tracking
analysis (NTA) software. Ad-wtcapsid and unPEGylated or PEGylated Ad-HVR1 vectors
(1.7 × 106 VP/μl) were analyzed. 100 nm Latex beads (1.4 × 106 beads/μl) were used as
control. Results are given as mean ± standard deviation of ﬁve independent measure-
ments. UnPEG: unPEGylated.
Vector Modiﬁcation Particle size
Latex beads (100 nm) – 100 ± 0.5 nm
Ad-wtcapsid unPEG 111 ± 0.2 nm
Ad-HVR1 unPEG 113 ± 0.8 nm
2K-PEG 116 ± 1.0 nm
5K-PEG 118 ± 0.8 nm
20K-PEG 133 ± 0.7 nmmuMT−/− mice, the latter being deﬁcient in IgG, IgM, and IgA (Fig.
4a). Ad-HVR1 vector particles were only partially neutralized in Ad-
naïve C57BL/6 plasma (mean ﬂuorescence intensity (MFI)-value:
92.5). In contrast, Ad-HVR1-ΔFX particles were completely neutralized
(MFI-value: 0.98; p b 1.1 × 10−6 compared to Ad-HVR1 in plasma). Im-
portantly, antibody-deﬁcientmuMT−/− plasma did not neutralize Ad-
HVR1-ΔFX particles (MFI-value: 133; p b 0.001 compared to Ad-HVR1-
ΔFX in C57BL/6 plasma). This data conﬁrmed a natural antibody-depen-
dent neutralization mechanism. Moreover, heat-inactivated C57BL/6
plasma did not neutralize Ad-HVR1-ΔFX vector particles (MFI-value:
97; p b 7.3 × 10−10 compared to non-heated C57BL/6 plasma), indicat-
ing a complement-dependent mechanism. This ﬁnding is in line with
the previous observations by Xu et al. that shielding of Ad5 by FX pro-
tects the vector from neutralization by mouse serum [5]. Results were
conﬁrmed with plasma from NMRI and BALB/c mice (data not shown).
To assess whether PEGylation of HVR1 could shield the vector parti-
cles from neutralization, we performed a neutralization assay over a
range of different vector particle/plasma ratios (Fig. 4b). After incuba-
tion in PBS (negative control without plasma; data point 0 μl in Fig.
4b) all vectors transduced A549 cells to a similar extent (MFI-values:
unPEGylated Ad-HVR1: 162.5 ± 1.3; unPEGylated Ad-HVR1-ΔFX:
189.6 ± 9.5; 2K-PEG-Ad-HVR1-ΔFX: 197.6 ± 3.8; 5K-PEG-Ad-HVR1-
ΔFX: 176 ± 6). At the highest vector particle/plasma ratio (data point
1 μl in Fig. 4b) only Ad-HVR1-ΔFX particles were neutralized (MFI-
value: 51.6 ± 9.2), presumably due to a lack of the natural FX shield.
UnPEGylated Ad-HVR1(MFI-value: 286.3 ± 23.2), 2K-PEG-Ad-HVR1-
ΔFX (MFI-value: 307 ± 15.4), and 5K-PEG-Ad-HVR1-ΔFX (MFI-
value:355 ± 12.1) even exhibited a higher transduction of cells com-
pared to that of their counterparts incubated in PBS (data point 0 μl,
Fig. 4b). Starting at the second highest vector particle/plasma ratio all
Fig. 2. PEGylation of HVR1 reduced binding of the vector capsid to immobilized FX and
eliminated biological effects of FX in vitro. (a) Surface plasmon resonance analysis was
performed to determine binding of the vector capsid to human FX. Different dilutions of
Ad-wtcapsid or PEGylated and unPEGylated Ad-HVR1 and Ad-HVR1-ΔFX vectors (single
values or duplicates; ranging from 1 × 109 VP/μl to 6.25 × 107 VP/μl) were injected.
Human FX was immobilized on the chip. Since the quality of the FX surface decreased
over time, binding of modiﬁed vectors to FX was quantiﬁed by normalizing the response
of modiﬁed vectors at concentrations of 1 × 109 VP/μl to the reference Ad-wtcapsid
vector (1 × 109 VP/μl), which had been injected immediately before. Circle areas
correspond to the percentage of residual FX-binding (n = 2). (b) To measure FX-
dependent cell transduction, A549 cells were transduced with pMOI 1000 using
unPEGylated or PEGylated Ad-HVR1-ΔCAR and Ad-HVR1-ΔCAR-ΔFX vectors in absence
or presence of physiological FX concentrations (8 μg/ml). EGFP expression was analyzed
by ﬂow cytometry 24 h p.i. (n = 2). Results are given as mean ± standard deviation.
AU: arbitrary units, RU: response units, unPEG: unPEGylated.
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manner.
Taken together, the results showed that 2K- or 5K-PEGylated Ad-
HVR1-ΔFX vector particles were protected from neutralization at high
vector particles/plasma ratios (compare MFI-values of data point 0 μl
and data point 1 μl in Fig. 4b). This indicated that position-speciﬁc
PEGylation of HVR1 successfully replaced the FX-mediated shielding
of vector particles from natural antibodies and complement.
3.5. Increased hepatocyte transduction by PEGylated Ad-HVR1-ΔCAR-ΔFX
vectors in antibody-deﬁcient mice
Liver transduction by Ad5 vectors is extremely sensitive to inhibition
by natural IgM antibodies, especially when the vector is not shielded by
FX [5,47–49]. As a result, liver transduction by Ad5 vectors is higher in
antibody-deﬁcient mice than in wild-type mice [47,49]. To determine
whether increased hepatocyte transduction in BALB/c mice by
PEGylated Ad-HVR1-ΔCAR-ΔFX (Fig. 3a) could be completely attributed
to avoiding natural antibodies and complement, we examined liver
transduction in antibody-deﬁcient JHD mice. We injected 2 × 1010particles of unPEGylated or PEGylated Ad-HVR1-ΔCAR-ΔFX vectors via
the tail vein, and measured EGFP in liver homogenates at 72 h p.i. (Fig.
5). The data showed recovered hepatocyte transduction by
unPEGylated Ad-HVR1-ΔCAR-ΔFX in antibody-deﬁcient JHD mice that
was not observed in BALB/cmice (Fig. 3a). This ﬁnding of a FX-indepen-
dent hepatocyte transduction in the absence of natural antibodies is in
accordance with ﬁndings of Xu et al. [5]. Interestingly, results clearly
showed that 2K- and 5K-PEGylated Ad-HVR1-ΔCAR-ΔFX vectors exhib-
ited augmented liver transduction compared to unPEGylated vectors
(8-fold, p b 0.03; 14-fold, p b 0.05, respectively). 20K-PEG-Ad-HVR1-
ΔCAR-ΔFX vectors did not transduce hepatocytes.
Thus, improvement in liver transduction by 2K- and 5K-PEG seemed
to be attributed to more than only avoiding natural antibodies: 2K- and
5K-PEGylation of Ad-HVR1-ΔCAR-ΔFX vectors had beneﬁcial effects on
liver transduction even in mice that completely lacked antibodies.
3.6. PEGylation of HVR1 shielded vector particles from complement
Previously, it was shown in vivo that FX is not required for liver
transduction in C1q or C4 knockout mice. In vitro it has been demon-
strated that capsid-bound FX reduces the C3 convertase activity and
shields the vector from opsonization by C3 [5]. Since the in vitro assays
demonstrated that PEGylation of HVR1 substituted a FX-mediated
shielding and prevented complement-dependent neutralization of par-
ticles in murine plasma (Fig. 4a,b), we analyzed the binding of C3b to
PEGylated particles by ELISA. Ad-coated plates were incubated with
hirudinized murine plasma that had physiological Ca2+ concentrations
to allow binding of FX and activation of the classical complement path-
way (Fig. 6, left panel). In accordancewith literature, results showed en-
hanced C3b-binding to Ad-HVR1-ΔFX vector particles compared to Ad-
HVR1 (p b 6.7 × 10−8). However and interestingly, PEGylation of HVR1
signiﬁcantly reduced the binding of C3b to the capsid in a PEG size-de-
pendent manner (compared to unPEGylated Ad-HVR1-ΔFX: 2K-PEG:
p b 2.5 × 10−7; 5K-PEG: p b 2.2 × 10−6; 20K-PEG: p b 3.2 × 10−10).
By the use of an αAd5 ﬁber antibody, we conﬁrmed equal coating efﬁ-
ciencies for all vectors (Fig. 6, right panel). Thus, PEGylation of HVR1
substituted FX and shielded the vector capsid from opsonization by
the complement system.
3.7. PEGylation of HVR1 prevented antibody/complement-mediated uptake
of Ad5 by murine macrophages
Xu et al. demonstrated that both natural antibodies and complement
contribute to the sequestration of Ad5 vector particles by KC [6]. Since
the in vitro neutralization assays conﬁrmed that PEGylation of HVR1
had substituted FX-mediated shielding (Figs. 4b and 6), we analyzed
the uptake of the geneti-chemically modiﬁed vector particles by the
murine macrophage cell line Raw264.7 after 2 h incubation. To mimic
the in vivo situation, the uptake of vector particles was analyzed in the
presence of Ad-naïve hirudinized murine plasma. The uptake of vector
particles into murine macrophages after incubation in C57BL/6 plasma
was increased for Ad-HVR1-ΔFX compared to Ad-HVR1 (7.7-fold;
p b 6.7 × 10−4; Fig. 7a). This effectwas abolishedwhen vectors were in-
cubated in heat-inactivated plasma (p b 7.3 × 10−4; Fig. 7a) or plasma
from antibody-deﬁcient muMT−/− mice (Fig. 7b). This indicated a
complement- and natural antibody-dependent uptake mechanism. Im-
portantly, PEGylation largely ablated the uptake of Ad-HVR1-ΔFX vec-
tors (2K-PEG: p b 0.04; 5K-PEG: p b 0.03; 20K-PEG: p b 0.002; Fig. 7c).
The results were conﬁrmed with a second murine macrophage cell
line J774A.1 (data not shown) and with plasma from NMRI and BALB/
c mice (data not shown).
3.8. Improved pharmacokinetics of PEGylated Ad-HVR1-ΔCAR-ΔFX vectors
The uptake of Ad5 by macrophages is an efﬁcient and rapid mecha-
nism [1,8]. To analyze if PEGylated vector particles might exhibit
Fig. 3. Increased FX-independent hepatocyte transduction by PEGylated Ad-HVR1-ΔCAR and Ad-HVR1-ΔCAR-ΔFX vectors. (a) 2 × 1010 VPwere injected into the tail vein of BALB/c mice.
Mice were sacriﬁced 72 h later and EGFP expression in liver homogenates was measured by ﬂuorometic analysis (n = 4–13). (b) Fluorescence microscopy of EGFP expression in cryo-
sections (6 μm) of liver and spleen. Scale bar = 0.5 mm. AU: arbitrary units, unPEG: unPEGylated, *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005.
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PEGylated Ad-HVR1-ΔCAR and Ad-HVR1-ΔCAR-ΔFX vector particles
into the tail vein of BALB/c mice and quantiﬁed the Ad5 genomes in
blood at several time points early after injection by qPCR (Fig. 8a). The
control vectors Ad-wtcapsid and Ad-HVR1-ΔCAR, both of which
showed normal FX-binding (Fig. 2a), were rapidly cleared from the
blood stream within 20 min (AUC: 8.9 × 108 and 1.6 × 109, respective-
ly). Compared to Ad-wtcapsid, unPEGylated Ad-HVR1-ΔCAR-ΔFX vec-
tor particles showed a slightly slower clearance from blood (AUC:
2.2 × 109). In contrast, PEGylation of Ad-HVR1-ΔCAR-ΔFX vectors sig-
niﬁcantly increased the vector circulation in blood in a PEG size-depen-
dent manner (AUC: 2K-PEG: 9.3 × 109; 5K-PEG: 1.3 × 1010; 20K-PEG:
1.7 × 1010). 5K- and 20K-PEGylated Ad-HVR1-ΔCAR-ΔFX vector parti-
cles were not cleared within the evaluated period of 20 min (for AUC
values see Table 3; for p-values see Table S1). Importantly, we demon-
strated that 5K- and 20K-PEGylated vector particles were not cell-associated, thus excluded ‘hitchhiking’ of particles on blood cells, by an-
alyzing the blood cell fraction and the plasma fraction 20 min p.i. sepa-
rately (Fig. 8b).
To estimate the toxicity of PEGylated vector particles with improved
pharmacokinetics, we incubated hirudinized murine whole blood with
unPEGylated or PEGylated Ad-HVR1 and Ad-HVR1-ΔFX for 6 h at 37 °
C and determined the IL-6 concentration by ELISA. Results clearly re-
vealed that PEGylated Ad-HVR1-ΔFX vector particles did not signiﬁ-
cantly enhance IL-6 secretion compared to unPEGylated Ad-HVR1-
ΔFX or Ad-HVR1 particles (Fig. 8c).
3.9. PEGylation of HVR1 inhibited scavenger receptor-mediated uptake of
Ad5 by macrophages
Xu et al. demonstrated that uptake of Ad5 vector particles bymacro-
phages is not only antibody- and complement- but also scavenger
Fig. 4. PEGylation of HVR1 inhibited complement-dependent neutralization of ΔFX vector particles by mouse plasma. (a) Transduction of A549 cells by 2 × 107 VP of Ad-HVR1 and Ad-
HVR1-ΔFX vectors (pMOI 1000) in presence of hirudinized C57BL/6 plasma or plasma from antibodies-deﬁcient muMT−/−mice with a vector particle/plasma ratio of 1.3 × 106 VP/
μl. To destroy the complement system plasma samples were heated before use at 56 °C for 30 min. Cell transduction was analyzed by measuring the EGFP expression 24 h p.i. (b)
Transduction of A549 cells by 2 × 107 VP of unPEGylated Ad-HVR1 and unPEGylated or 2K- and 5K-PEGylated Ad-HVR1-ΔFX (pMOI 1000) after incubation in 1 μl, 2 μl, 5 μl, 10 μl or
15 μl of hirudinized C57BL/6 plasma was analyzed by measuring the EGFP expression 24 h p.i. (n = 3). The vector particle/plasma ratio when using 1 μl plasma corresponded to the
vector particle/plasma ratio in the in vivo studies. Results are given as mean ± standard deviation. AU: arbitrary units, **p ≤ 0.005, ***p ≤ 0.0005.
387L. Krutzke et al. / Journal of Controlled Release 235 (2016) 379–392receptor-mediated [6]. Scavenger receptors can bind negatively charged
molecules [22] and the zeta potential analysis (Fig. 1b) had revealed a
PEG size-dependent reduction of the negative surface charge forFig. 5. Increased hepatocyte transduction by PEGylated Ad-HVR1-ΔCAR-ΔFX vectors in
antibody-deﬁcient JHD mice. 2 × 1010 VP were injected into the tail vein of antibody-
deﬁcient JHD mice. Mice were sacriﬁced 72 h later and EGFP expression in non-perfused
liver homogenates was measured by ﬂuorometic analysis (n = 2 for buffer control, n =
3–4 for the vector-treated groups). Results are given as mean ± standard deviation. AU:
arbitrary units, unPEG: unPEGylated.PEGylated particles. Therefore, the scavenging of PEGylated particles
was analyzed with the scavenger receptor-expressing cell line J774A.1
[23] in the presence and absence of polyinosinic acid (poly-(I)) as scav-
enger receptor inhibitor (Fig. 9a). Results clearly demonstrated a scav-
enger receptor-mediated uptake of unPEGylated Ad-HVR1-ΔFX vector
particles, which was 3-fold lower when cells had been pre-treated
with poly-(I). PEGylation reduced the uptake of particles by J774A.1
cells in a PEG size-dependent manner (uptake reduction of PEGylated
Ad-HVR1-ΔFX particles compared to unPEGylated Ad-HVR1-ΔFX parti-
cles: 2K-PEG: 1.7-fold, p b 0.006; 5K-PEG: 3-fold, p b 1.1 × 10−4; 20K-
PEG: 3.6-fold, p b 1.3 × 10−4). Transduction of scavenger receptor-neg-
ative A549 cells by unPEGylated Ad-HVR1-ΔFX vector particles revealed
similar EGFP expression levels in absence or presence of poly-(I). Hence
poly-(I) did not interfere with vector or cell integrity (Fig. 9b).
Taken together, position-speciﬁc PEGylation diminished antibody-
and complement-dependent as well as charge pattern-mediated scav-
enging by macrophages. Since improved evasion from macrophages
can be directly linked to elevated hepatocyte transduction in vivo [8,
21,23,39], the evasion from macrophages likely contributed to the
strong liver transduction in vivo (Figs. 3 and 5).
3.10. FX shielded Ad5 from neutralization by naïve human plasma
To our knowledge, FX-mediated shielding from neutralization was
so far only shown in mice, guinea pigs and rats [5,26]. To investigate if
the effect of a FX-mediated shielding also occurs in human blood, we
performed an in vitro neutralization assay as described before with
hirudinized human plasma from healthy donors (Fig. 10). Prior to the
assay, the plasma was tested by ELISA for anti-Ad IgGs and classiﬁed
to be naïve or anti-Ad IgG positive. Both Ad-HVR1 and Ad-HVR1-ΔFX
Fig. 6. PEGylation of HVR1 reduced binding of complement protein 3b to the vector capsid. 3 × 109 VP were coated on 96-well plates and were incubated with or without hirudinized
murine plasma (diluted 1:5 in PBS with physiological Ca2+ concentration) for 1 h. Coating efﬁciency and binding of C3b to vector capsids was determined by ELISA. Results are given
as mean ± standard deviation. (n = 6); unPEG: unPEGylated. ***p ≤ 0.0005.
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EGFP-positive cells; 3% EGFP-positive cells, respectively). In contrast,
while Ad-HVR1 was not neutralized by Ad-naïve human plasma (PBS:
80% EGFP-positive cells; plasma: 75% EGFP-positive cells), substantial
neutralization was observed for Ad-HVR1-ΔFX in the presence of Ad-
naïve human plasma (PBS: 70% EGFP-positive cells; Ad-naïve plasma:
5% EGFP-positive cells, p b 1.1 × 10−10; Ad-HVR1-ΔFX incubated in
Ad-naïve plasma compared to Ad-HVR1 incubated in Ad-naïve plasma:
p b 4.1 × 10−8). Heat-inactivated Ad-naïve human plasma did not neu-
tralize Ad-HVR1-ΔFX vector particles (85% EGFP-positive cells; com-
pared to non-heated Ad-naïve plasma: p b 7.6 × 10−11). This
conﬁrmed a complement-dependentmechanism. Although not directly
shown here, it may be possible that besides the obvious role of comple-
ment, also natural IgM antibodies contributed to the neutralization of
ΔFX vector particles. Thus, data conﬁrmed that the phenomenon of
FX-mediated shielding from neutralization in plasma also applies to
human blood.
3.11. Binding of ΔFX vectors to human blood cells
Binding of Ad5 to human erythrocytes is mediated either by attach-
ment of the ﬁber knob to CAR or by αAd IgG-mediated binding to com-
plement receptor 1 (CR1). Both receptors are expressed on human butFig. 7. PEGylation of HVR1 prevented natural antibody- and complement-dependent uptake ofΔ
murine plasma in a ﬁnal concentration of 6× 106 VP/μl. Subsequently, Raw264.7 cellswere incub
Ad5 was measured by qPCR analysis. All samples were normalized using murine β-actin copy
destroy the complement system plasma samples were heated before use at 56 °C for 30 min.
antibody-deﬁcient muMT−/− mice. (c) Ad-HVR1-ΔFX vectors, modiﬁed with 2K-, 5K- and
standard deviation. UnPEG: unPEGylated. *p ≤ 0.05, **p ≤ 0.005.notmurine erythrocytes [14]. To assess whether FX-binding ablation af-
fect attachment of vectors to human blood cells, Ad-HVR1, Ad-HVR1-
ΔCAR and Ad-HVR1-ΔCAR-ΔFX vector particles were incubated with
hirudinized human whole blood from ELISA-tested Ad-naïve donors.
Blood samples were spiked or not spiked with IVIG, a mixture of IgGs
puriﬁed from pooled human plasma samples and containing αAd5
IgGs [50]. Cell and plasma fractions were separated by centrifugation
and the Ad5 genome contentwas quantiﬁed by qPCR (Fig. 11). In agree-
ment to the ﬁndings by Carlisle et al. [14] the results revealed for Ad-
HVR1 and Ad-HVR1-ΔCAR vector particles a CAR- and IgG-mediated
binding to human blood cells, both of which mechanisms resulted in
up to 90% cell-associated vector particles (Fig. 11a and b). Incubation
of Ad-HVR1 vector particles with ELISA-tested anti-Ad IgG-positive
hirudinized human whole blood and subsequent ﬁcoll gradient centri-
fugation to separate the different blood cell types, conﬁrmed that the
vast majority of vector particles bound to erythrocytes (Fig. S4). Inter-
estingly, N75% of Ad-HVR1-ΔCAR-ΔFX vector particles attached to
human blood cells after incubation with Ad-naïve human whole blood
(p b 9.3 × 10−11 compared to Ad-HVR1-ΔCAR), thus in a CAR- and
IgG-independent manner (Fig. 11c). Even though not directly shown
here, it may be possible that this binding was mediated by natural anti-
bodies and complement, which bound to the capsids of ΔFX vector
particles.FX vector particles bymacrophages. Vector particles were incubated in PBS or hirudinized
atedwith vector:PBS or vector:plasma solution (pMOI 2000) for 2 h at 37 °C. The uptake of
numbers. (a) Ad-HVR1 and Ad-HVR1-ΔFX vectors were incubated in C57BL/6 plasma. To
(b) Ad-HVR1-ΔFX vectors were incubated in PBS, plasma from C57BL/6 or plasma from
20K-PEG were incubated in C57BL/6 plasma (n = 2–5). Results are given as mean ±
Fig. 8. Improved pharmacokinetics after geneti-chemical Ad capsid modiﬁcation. (a) The pharmacokinetic proﬁle was determined by injection of 2 × 1010 VP into the tail vein of BALB/c
mice and collection of blood samples (20 μl) at distinct time points within 20 min p.i. Genomic DNA was extracted and analyzed for the Ad5 genome copy number by qPCR analysis. (b)
20min p.i. blood samples (100 μl)were collected by puncturing the heart. Blood cells and plasmawere separated by centrifugation, andDNAwas extracted from the cell pellet. Results are
given as percentage of recovered vector particles in the cell pellet to total recovered vector particles in 20 μl whole blood at 20 min p.i. All samples were normalized using murine β-actin
copy numbers. Depicted statistic were calculated for Ad5 genome copy numbers compared to Ad-wtcapsid vectors detected after 20min. Results are given asmean± standard deviation
(n= 3–9). (c) 4 × 109 VPwere incubated ex vivowith 300 μl hirudinized murine whole blood for 6 h at 37 °C. Plasmawas separated by centrifugation for 10min at 1.000 ×g and the IL-6
concentration was determined by ELISA. (n = 3) unPEG: unPEGylated, *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005.
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Systemic delivery of gene transfer vectors is essential to treat large
organ systems or disseminated solid tumors and metastasis. However,
gene transfer vectors have to overcome multiple barriers before they
can reach their target tissue through the blood stream. Some of these
barriers already arise very early upon contact of the vectorswith cellular
or non-cellular blood components and dictate the fate of the vector par-
ticles after systemic delivery. In particular, the clinical utility of Ad5-
based vectors is severely hampered by a plethora of such vector-blood
interactions. Ad5-based vectors bind blood coagulation factor X [12,
13] and this binding controls the tropism of the vector [12,13,28,30]. Si-
multaneously, complement system, natural antibodies, and macro-
phages act as innate defense line against pathogens and inactivate
Ad5 vectorswith remarkable efﬁciency [1,6,9,10,49]. Noteworthy, inter-
actions between the vector and blood components appear to be very
closely intertwined. As a result, Ad vectors rationally engineered to
overcome one speciﬁc barrier (e.g. FX-imposed hepatocyte tropism)Table 3
Increased vector persistence in blood by minimal geneti-chemical modiﬁcation. Calcula-
tion of area under the curve (AUC) between 2 min and 20min. Results are given as x-fold
increase of AUC compared to control vector Ad-wtcapsid. Calculations were done using
SciDAVis 1.D5 software. UnPEG: unPEGylated.





20K-PEG 19.0may be eliminated by another barrier (e.g. complement and natural an-
tibodies) in a sometimes surprising and difﬁcult to predict way [5]. The
geneti-chemically modiﬁed vectors presented here provide a tool to
gain deeper insight into the complex network of Ad5 vector-blood in-
teractions. We demonstrated that binding of FX to Ad5 vector particles
is not required for liver transduction. In addition, the pharmacokinetics
of systemically delivered Ad5 vectors was signiﬁcantly improved by ra-
tionally selected capsid modiﬁcations in combination with minimal po-
sition-speciﬁc PEG shielding. The data presented here provide
signiﬁcant new insight into how PEGylation improves Ad5 vector prop-
erties and suggest that geneti-chemically modiﬁed vectors with posi-
tion-speciﬁc PEG shields may be developed into clinically useful
therapeutic agents.
Previously, Xu et al. had demonstrated that FX was not required for
liver transduction in transgenic mice that lacked antibodies, C1q, or C4
complement components [5]. Since capsid-bound FX protected vector
particles from complement andnatural antibodies, the authors assigned
a shielding function to capsid-bound FX. The data presented here indi-
cate that the shield established by FX can be substituted by PEGmoieties
coupled to HVR1 of the hexon capsomere. Ad-HVR1-ΔFX speciﬁcally
PEGylated at HVR1 with 5K-PEG moieties was unable to bind to FX as
evidenced by SPR analysis (Fig. 2a), did not exhibit augmented trans-
duction in the presence of FX in vitro (Figs. 2b and S3), but transduced
liver to an extent even higher than the Ad-wtcapsid vector (Fig. 3a). Im-
portantly, its unPEGylated counterpart Ad-HVR1-ΔFX was susceptible
to complement (Fig. 4a) and failed to transduce liver (Fig. 3a). This
data proves that approximately 700 PEG moieties coupled to hexon
HVR1 established an efﬁcient shield to protect the vector particles
from complement and natural antibodies (Figs. 4b and 6) and subse-
quent uptake by macrophages (Fig. 7). Since PEG as a hydrophilic
Fig. 9. PEGylation of HVR1 inhibited scavenger receptor-mediated uptake of particles by macrophages. (a) J774A.1 cells were treated or not with 30 μg/ml poly-(I) for 1 h at 37 °C.
Subsequently, cells were incubated with unPEGylated and PEGylated Ad-HVR1-ΔFX vector particles (pMOI 2000) for 2 h. Cells were washed and incubated for 24 h at 37 °C.
Subsequently, the uptake of Ad5 by the cells was measured by qPCR analysis (n = 6). All samples were normalized using murine β-actin copy numbers. (b) A549 were treated or not
with 30 μg/ml poly-(I) for 1 h at 37 °C. Subsequently, cells were incubated with Ad-HVR1-ΔFX vector particles (pMOI 1000) for 2 h, washed, and the EGFP expression was analyzed
24 h p.i. by ﬂow cytometry analysis (n = 3). Results are given as mean ± standard deviation. AU: arbitrary units, unPEG: unPEGylated, *p ≤ 0.05, ***p ≤ 0.0005.
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mains elusive which receptor was utilized by the PEGylated particles
for hepatocyte transduction. Interestingly, Zaiss et al. recently showed
that heparan sulfate proteoglycans expressed on the surface of hepato-
cytes are dispensable for Ad5 liver transduction [51]. In addition, the au-
thors demonstrated that CAR was not responsible for liver transduction
in transgenic mice lacking HSPG expression on hepatocytes [51]. These
ﬁndings are in agreement with and provide complementary informa-
tion to the results presented here: Ad5 particles can transduce hepato-
cytes even in the absence of HSPGs [51] when FX provides a shield
against complement and natural antibodies [5]. If the shield established
by FX on the capsid is substituted by PEG molecules, neither FX- nor
CAR-binding are required for liver transduction (Fig. 3a).
Thus, it appears very likely that Ad5 can utilize a so far unknown re-
ceptor for liver transduction. Obviously, to fully elucidate the biology of
liver transduction by Ad5 (and presumably other types) more research
efforts are required.
Our data further suggest that both Ad5 particle charge and size are
important parameters that can bemodulated by geneti-chemical capsid
modiﬁcations. While we do not provide direct evidence, our dataFig. 10. Neutralization of ΔFX vector particles in Ad-naïve human plasma. Transduction of
A549 cells by 2 × 107 VP of Ad-HVR1 and Ad-HVR1-ΔFX vectors (pMOI 1000) in the
presence of hirudinized plasma from Ad-naïve or anti-Ad IgG-positive human plasma
with a vector particles/plasma ratio of 1.3 × 106 VP/μl. To destroy complement system,
plasma samples were heated before use at 56 °C for 30 min. Transduction of cells was
analyzed by measuring the EGFP expression 24 h p.i. by ﬂow cytometry. Results are
given as mean ± standard deviation (n = 5–10). ***p ≤ 0.0005.suggest that reducing the net negative charge of Ad5 particles might fa-
cilitate evasion from scavenging by macrophages (Fig. 9a) and enables
prolonged circulation of vector particles in blood (Fig. 8a). The data on
reduced scavenging is in agreement to ﬁndings by Khare et al. for
Ad5/6 chimeric vectors with hexon HVRs derived from Ad6 that efﬁ-
ciently evaded from scavenging by Kupffer cells in vivo [21,24]. Ad6
has a more neutral net charge compared to Ad5 [24]. Interestingly, we
found that vector particles shielded with 2K-PEG or 5K-PEG with a re-
duced negative net charge (Fig. 1b) exhibited slightly augmented infec-
tivity in vitro (Fig. 1d). This ﬁnding was corroborated on various cell
lines (data not shown). We speculate that the reduced negative charge
may facilitate binding to cell surfaces by reducing charge repulsion ef-
fects. This may also contribute to the improved liver transduction by
2K- and 5K-PEGylated vectors (Figs. 3a and 5).
Position-speciﬁc PEGylation in combination with genetic point mu-
tations signiﬁcantly reduced the blood clearance of Ad5 vector particles
after intravenous vector injection (Fig. 8a). Compared to previous ap-
proaches based on amine-directed chemical modiﬁcation that
employed 14,000 amine groups per capsid for polymer coupling [31,
35], we achieved similar results by position-speciﬁc coupling of only
700 polymer molecules. Ex vivo data conﬁrmed that PEGylation did
not increase vector toxicity in blood (Fig. 8c). Considering that im-
proved pharmacokinetics might allow for a reduction of the required
vector dose, position-speciﬁc PEGylation could indirectly contribute to
a dampened vector toxicity. 5K-PEG-Ad-HVR1-ΔCAR-ΔFX showed a
19-fold improved AUC between minutes 2 and 20 compared to Ad5
withwildtype capsid. Nevertheless, 72 h after injection the vector parti-
cles transduced hepatocytes with high efﬁciency (Fig. 3a). It will be im-
portant to analyze the biodistribution of 5K-PEG-Ad-HVR1(-ΔCAR)-
ΔFX particles in tumor models with well-vascularized tumors to assess
if the improved pharmacokinetics, as observed here, is sufﬁcient to ac-
cumulate the vector particles in tumors via the enhanced permeability
and retention effect [52]. In parallel, an identiﬁcation of the so far un-
known receptor for liver transduction will pave the way for additional
vector improvements.
While the infectivity of Ad vector particles can be impaired in partic-
ular by extensive polymer wrapping [32–35], the position-speciﬁc cou-
pling of PEG moieties with a size of up to 5K did not diminish vector
infectivity (Fig. 1d). In contrast, coupling of 20K-PEG molecules ren-
dered the vector particles non-infectious (Fig. 1d). While the molecular
reason for this observation remains unknown, it indicates that success-
ful modiﬁcation of Ad vector with synthetic polymers depends on care-
ful selection of both the site of modiﬁcation and the polymer size.
Fig. 11. Binding ofΔFX vectors to human blood cells. 1 × 108 vector particles were incubated with 200 μl hirudinized Ad-naïve humanwhole blood± 10mg/ml of human IgG (IVIG) in a
ﬁnal volume of 300 μl for 30min at 37 °C. Blood cells and plasmawere separated by centrifugation, followed by genomic DNA extraction and analysis of the Ad5 content by qPCR. Results
are given as mean percentage ± standard deviation of recovered vector particles from total recovered vector particles in both the cell and plasma fraction. Ad5 DNA copy number was
normalized using human β-actin copy numbers. (a) Ad-HVR1 vector (n = 6). (b) Ad-HVR1-ΔCAR vector (n = 9). (c) Ad-HVR1-ΔCAR-ΔFX vector (n = 6–8). ***p b 0.0005.
391L. Krutzke et al. / Journal of Controlled Release 235 (2016) 379–392Previous data suggest that restrictions imposed by the size of the
coupled polymer can be circumvented by choosing a bioresponsive cou-
pling mode that allows the separation of polymer and vector particles
after cell entry [44,53]. Such techniques can easily be applied for the
vectors presented here [44].
Finally, our data emphasize the importance of extensive analysis of
vector-blood interactions to understand barriers for gene delivery on a
cellular and molecular level. While most of the data presented here
were obtained by using mice and mouse blood, we also provide hints
that the ﬁndings can be transferred to humans. The data demonstrate
that capsid-bound FX can shield Ad5 particles from human blood com-
ponents, namely complement (Fig. 10). In addition, we demonstrated
that inhibition of FX-binding to vector capsids resulted in increased
binding of particles to human blood cells (Fig. 11c). In agreement with
the mouse data, this demonstrates the need to substitute the natural
FX shield by a rationally designed synthetic shield - in order to enhance
vector maintenance and improve the clinical applicability of Ad5 and
presumably other Ad-based vectors.
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